Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment

Table 1 The baseline characteristics of patients

Characteristics	n (%)
Age
≤ 60	52 (77.6)
> 60	15 (22.4)
Gender
Male	59 (88.1)
Female	8 (11.9)
ECOG PS
0	52 (77.6)
1	15 (22.4)
HBsAg
Positive	53 (79.1)
Negative	14 (20.9)
Child-Pugh Class
Class A	45 (67.2)
Class B	22 (32.8)
Tumor size, cm
≤ 10	43 (64.2)
> 10	24 (35.8)
No. of intrahepatic tumors
≤ 3	32 (47.8)
> 3	35 (52.2)
Baseline AFP level, ng/mL
≤ 400	29 (43.3)
> 400	38 (56.7)
PVTT
Absent	23 (34.3)
Present	44 (65.7)
HVTT
Absent	50 (74.6)
Present	17 (25.4)
Metastasis
Absent	54 (80.6)
Present	13 (19.4)

ECOG PS: Eastern Cooperative Oncology Group performance status; HBsAg: Hepatitis B surface antigen; AFP: Alfa-fetoprotein; PVTT: Portal vein tumor thrombus; HVTT: Hepatic vein tumor thrombus.